GFAP and early-onset autosomal dominant Alzheimer disease: In the context of neurodegenerative disorders, such as Alzheimer's disease (AD), the measurement of blood GFAP has demonstrated heightened efficacy compared to CSF levels in capturing amyloid-β (Aβ) pathology, particularly in the initial stages of the AD spectrum [44].